A Phase III Randomized Double-Blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-Induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2017
Price : $35 *
At a glance
- Drugs Dapsone (Primary)
- Indications Exanthema
- Focus Therapeutic Use
- 10 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2015 Planned End Date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 02 Mar 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.